HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B
Lilly Yuen, Peter A Revill, Gillian Rosenberg, Josef Wagner, Margaret Littlejohn, Julianne Bayliss, Kathy Jackson, Susanna K Tan, Anuj Gaggar, Kathryn Kitrinos, Mani Subramanian, Ed Gane, Henry LY Chan, Xin Li, Scott Bowden, Stephen Locarnini, Alexander Thompson
Journal of Viral Hepatitis | WILEY | Published : 2020
Nucleos(t)ide analouges (NUC) treatment prevents progression of liver fibrosis in subjects with chronic hepatitis B (CHB). However, risk for hepatocellular carcinoma (HCC) persists despite viral suppression. Specific HBV variants have been associated with adverse outcomes, including HCC, however the frequency of these variants during the seemingly benign immunotolerant (IT) phase is unknown. Next generation sequencing and detailed virological characterization on a cohort of treatment-naïve IT subjects was performed to determine the frequency of clinically relevant viral variants. Samples from 97 subjects (genotype B/C 55%/45%, median HBV-DNA 8.5 log10 IU/mL, median HBsAg 4.8 log10IU/mL, medi..View full abstract
The study was funded in part by Gilead Sciences.